nomlabofusp

Nomlabofusp is a recombinant fusion protein and investigational protein replacement therapy designed to treat Friedreich's ataxia (FA) by directly addressing the underlying deficiency of frataxin, a mitochondrial protein essential for normal cellular energy production. The drug consists of a cell-penetrating peptide fused to human frataxin, including a mitochondrial targeting sequence that enables delivery of functional frataxin into mitochondria. By increasing intramitochondrial frataxin levels, nomlabofusp aims to restore electron transport chain function and improve metabolic activity in patients with FA. Clinical trials have shown dose-dependent increases in tissue frataxin concentrations and suggest potential disease-modifying effects. Nomlabofusp is administered subcutaneously and has received multiple regulatory designations, including Orphan Drug status in the US and EU, Fast Track designation from the FDA, Rare Pediatric Disease designation from the FDA, and PRIME designation from the EMA[1][2][3][5][6].

Other names

nomlabofusp